ERIM
STML

Eagle Ridge Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Eagle Ridge Investment Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,000
Closed -$171K – 59
2014
Q4 		$171K Buy
+10,000
New +$144K 0.08% 55

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eagle Ridge Investment Management's STML Position: Q1 2015 in Review

Eagle Ridge Investment Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2015, closing a stake of 10,000 shares — an estimated $171K sold.

Eagle Ridge Investment Management first reported a position in STML in Q4 2014 and held it in 1 quarter. The position peaked at $171K in Q4 2014. 69 funds tracked by Wall St. Rank hold STML as of Q1 2015.

  • Eagle Ridge Investment Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Eagle Ridge Investment Management sold 10,000 Stemline Therapeutics, Inc. shares in Q1 2015, an estimated $171K.
  • Eagle Ridge Investment Management first reported a position in Stemline Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • Eagle Ridge Investment Management's Stemline Therapeutics, Inc. position peaked at $171K in Q4 2014.
  • 69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2015.

Based on Eagle Ridge Investment Management's 13F filing for Q1 2015, filed 24 Apr 2015.